Rina Yarosh1, Michelle A Roesler2, Thomas Murray3, Adina Cioc4, Betsy Hirsch5, Phuong Nguyen6, Erica Warlick7,8, Jenny N Poynter9,10. 1. Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA. 2. Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA. 3. Division of Biostatistics, University of Minnesota, Minneapolis, MN, USA. 4. VA Medical Center, Minneapolis, MN, USA. 5. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. 6. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 7. Department of Medicine, Division of Hematology/Oncology, University of Minnesota, Minneapolis, MN, USA. 8. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. 9. Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA. poynt006@umn.edu. 10. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. poynt006@umn.edu.
Abstract
PURPOSE: Myelodysplastic syndromes (MDS) are classified as de novo and therapy-related (tMDS). We evaluated associations between MDS risk factors separately for de novo and tMDS. METHODS: The study population included 346 de novo MDS cases, 37 tMDS cases and 682 population controls frequency matched by age and sex. Polytomous logistic regression was performed to calculate odds ratios (OR) and 95% confidence intervals (CI). RESULTS: After adjustment, former smoking status (OR = 1.45, 95% CI: 1.10-1.93), personal history of autoimmune disease (OR = 1.34, 95% CI: 0.99-1.82) and exposure to benzene (OR = 1.48, 95% CI: 1.00-2.19) were associated with de novo MDS. Risk estimates for the associations between smoking, autoimmune disease, and benzene exposure were similar in magnitude but non-significant in tMDS cases. Among individuals with a previous diagnosis of cancer, de novo MDS cases and controls were more likely to have had a previous solid tumor, while tMDS cases more commonly had a previous hematologic malignancy. CONCLUSIONS: We observed similar associations between smoking, history of autoimmune disease and benzene exposure in de novo and tMDS although estimates for tMDS were imprecise due to small sample sizes. Future analyses with larger sample sizes will be required to confirm whether environmental factors influence risk of tMDS.
PURPOSE: Myelodysplastic syndromes (MDS) are classified as de novo and therapy-related (tMDS). We evaluated associations between MDS risk factors separately for de novo and tMDS. METHODS: The study population included 346 de novo MDS cases, 37 tMDS cases and 682 population controls frequency matched by age and sex. Polytomous logistic regression was performed to calculate odds ratios (OR) and 95% confidence intervals (CI). RESULTS: After adjustment, former smoking status (OR = 1.45, 95% CI: 1.10-1.93), personal history of autoimmune disease (OR = 1.34, 95% CI: 0.99-1.82) and exposure to benzene (OR = 1.48, 95% CI: 1.00-2.19) were associated with de novo MDS. Risk estimates for the associations between smoking, autoimmune disease, and benzene exposure were similar in magnitude but non-significant in tMDS cases. Among individuals with a previous diagnosis of cancer, de novo MDS cases and controls were more likely to have had a previous solid tumor, while tMDS cases more commonly had a previous hematologic malignancy. CONCLUSIONS: We observed similar associations between smoking, history of autoimmune disease and benzene exposure in de novo and tMDS although estimates for tMDS were imprecise due to small sample sizes. Future analyses with larger sample sizes will be required to confirm whether environmental factors influence risk of tMDS.
Authors: A Krishnan; S Bhatia; M L Slovak; D A Arber; J C Niland; A Nademanee; H Fung; R Bhatia; A Kashyap; A Molina; M R O'Donnell; P A Parker; I Sniecinski; D S Snyder; R Spielberger; A Stein; S J Forman Journal: Blood Date: 2000-03-01 Impact factor: 22.113
Authors: Anneclaire J De Roos; H Joachim Deeg; Lynn Onstad; Kenneth J Kopecky; Erin J Aiello Bowles; Mellissa Yong; Jon Fryzek; Scott Davis Journal: Am J Hematol Date: 2010-10 Impact factor: 10.047
Authors: Elizabeth A Duffy; Phuong L Nguyen; Adina Cioc; Erica Warlick; Michelle A Roesler; Jenny N Poynter Journal: Cancer Causes Control Date: 2020-04-13 Impact factor: 2.506